CON Stock Forecast & Price Target

Concentra Group Holdings is well positioned to benefit from resilient demand in occupational health, supported by an aging workforce, improving manufacturing and construction activity, and strong exposure to employer- and workers’ compensation reimbursement rather than government payor risk. Its 2Q performance showed 3.7% workers’ compensation visit growth, 4.9% revenue per visit growth, 27.9% organic growth in onsite health clinics, and adjusted EBITDA margins of 23.3%, while free cash flow nearly doubled to $121MM and net leverage fell to just under 3.0x. The company’s outlook is further strengthened by disciplined cost control, successful Nova and Pivot integrations, raised 2026 revenue of $2.325B-$2.375B and adjusted EBITDA of $485MM-$495MM, and an attractive pipeline for M&A and de novo expansion.

Concentra Group Holdings is viewed negatively because its earnings and utilization are highly tied to employment levels, so weaker labor markets can reduce work-related injuries and pressure demand across its occupational health centers and onsite clinics. The company also faces meaningful downside from state fee schedule changes, regulatory and audit risk, and execution risk tied to its development strategy, while any inability to hire and retain clinical staff or maintain key customer and workers’ comp payor relationships could further impair operating performance. Although valuation references ~11x to ~12.2x 2027E adjusted EBITDA, the outlook remains cautious because the business depends on favorable labor market dynamics and successful acquisition integration to sustain growth.